Fratto Maria Elisabetta, Santini Daniele, Vincenzi Bruno, Silvestris Nicola, Azzariti Amalia, Tommasi Stefania, Zoccoli Alice, Galluzzo Sara, Maiello Evaristo, Colucci Giuseppe, Tonini Giuseppe
Medical Oncology, University Campus Bio-Medico, Rome.
Front Biosci (Schol Ed). 2011 Jan 1;3(1):16-22. doi: 10.2741/s128.
The key role of epidermal growth factor receptor(EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.
表皮生长因子受体（EGFR）在肿瘤发生中的关键作用已在多种癌症类型中得到证实，因此近期的临床试验研究了其在不同情况下的活性/疗效。已开发出两种不同类型的EGFR靶向药物：西妥昔单抗和帕尼单抗等单克隆抗体，以及吉非替尼和厄洛替尼等酪氨酸激酶抑制剂。在本综述中，我们总结了潜在活性的临床前理论依据以及评估抗EGFR靶向药物在非结直肠癌消化系统癌症中的单药治疗以及与其他化疗或靶向药物联合治疗的最重要临床试验。通过使用生物标志物进行患者选择将确定哪些患者更有可能产生反应，有助于这些药物的成功应用。
